Adaptive Biotechnologies ADPT Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$49.64M+65.0% | -$59.46M+62.7% | -$79.6M+59.3% | -$121.24M+43.2% | -$141.89M+34.0% | ||
| $15.24M-10.7% | $16.13M-8.1% | $16.39M-11.4% | $16.57M-15.7% | $17.07M-16.0% | ||
| $51.26M-0.4% | $51.48M-4.0% | $51.6M-8.4% | $51.86M-10.8% | $51.46M-17.7% | ||
| $4.73M+204% | $8.65M+131% | $4M— | $8.67M— | $1.56M— | ||
| $2.58M— | $998K— | -$2.39M— | -$5.44M— | —— | ||
| —— | —— | —— | —— | -$5.05M— | ||
| —— | —— | $1.57M— | $447K— | —— | ||
| -$50K-117% | -$142K-426% | -$10K— | -$13K— | -$23K— | ||
| -$33.07M-189% | -$40.4M-284% | -$42.09M-182% | -$15.74M+11.5% | -$11.45M+50.6% | ||
| $1.7M0.0% | $1.7M-0.2% | $1.7M-0.4% | $1.7M-0.4% | $1.7M-0.2% | ||
| -$29.09M+65.9% | -$48.04M+49.5% | -$60.53M+44.8% | -$80.47M+37.8% | -$85.34M+37.0% | ||
| $2.5M-26.8% | $2.96M-19.2% | $2.4M-50.8% | $2.34M-68.0% | $3.41M-63.2% | ||
| —— | —— | $68.32M+16.0% | $56.33M-29.4% | $58.86M-47.1% | ||
| $17.45M+209% | $17.88M+7,319% | $8.87M+4,314% | $7.23M+3,961% | $5.65M+249% | ||
| $32.45M+475% | $30.4M+12,515% | $8.87M+4,314% | $7.23M+3,961% | $5.65M+249% | ||
| $26.93M— | $22.37M— | —— | —— | —— | ||
| $13.85M+54.8% | $12.64M+42.6% | $10.26M+21.6% | $9.48M+8.6% | $8.95M+5.1% | ||
| $1.69M-74.1% | $2.51M-69.4% | $3.68M-62.1% | $5.17M-50.2% | $6.52M-36.2% | ||
| $1.7M0.0% | $1.7M-0.2% | $1.7M-0.4% | $1.7M-0.4% | $1.7M-0.2% | ||
| $15.24M-10.7% | $16.13M-8.1% | $16.39M-11.4% | $16.57M-15.7% | $17.07M-16.0% | ||
| —— | —— | —— | —— | —— | ||
| -$11.02M-24.2% | -$10.45M-11.4% | -$10.76M-28.1% | -$9.83M-9.2% | -$8.87M+1.5% | ||
| —— | —— | $1.57M— | $447K— | —— | ||
| —— | —— | —— | —— | $1.35M-11.3% | ||
| $5.5M+5.4% | $5.36M+1.6% | $5.28M-2.4% | $5.21M-13.2% | $5.22M-19.5% | ||
| -$549K— | -$611K— | —— | —— | —— | ||
| —— | —— | —— | —— | -$2.25M+51.5% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | $1.91M— | —— | —— | ||
| -$30.95M+65.1% | -$50.36M+49.1% | -$62.94M+45.1% | -$82.81M+39.4% | -$88.76M+38.7% | ||
| -$30.95M+65.1% | -$50.36M+49.1% | -$62.94M+45.1% | -$82.81M+39.4% | -$88.76M+38.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Adaptive Biotechnologies generate?
- Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Adaptive Biotechnologies's free cash flow?
- After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
- Where does Adaptive Biotechnologies's cash flow data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
